Teva's migraine therapy meets Phase II endpoints

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said TEV-48125 ( LBR-101) met the primary endpoint of reducing headaches vs. placebo

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE